BRAF, a serine-threonine kinase in the RAS/RAF/MAPK signalling cascade, is mutated in 60–70% of melanomas and, to date, represents the most common mutation in this disease (Davies et al, 2002; Curtin et al, 2005). This evidence concerns the gene BRAF and melanoma.